Back to journals
Academic Journal

Clinical Drug Investigation

3 Papers Indexed in Blossom

Data updated

Research Footprint

Clinical Drug Investigation has 3 tracked papers indexed in Blossom (2022) from 22 authors, most often covering Ketamine, Esketamine and MDMA, across Suicidality, Depressive Disorders and PTSD.

Published Papers

Paywallindividual

Efficacy and Safety of Subcutaneous Esketamine in the Treatment of Suicidality in Major Depressive Disorder and Bipolar Depression

This open-label study (n=70) on suicidal ideation (SI) in patients with major depressive disorder (MDD) and bipolar depression (BD) finds that esketamine (1x p/w 6ws) led to significant reductions in SI at the end of the study (24h after last administration). There was no statistically significant difference between the two subpopulations.

Published
Journal
Clinical Drug Investigation
Authors
Surjan, J., Grossi, J. D., Del Porto, J. A., Delfino, S. R., De Oliveira Cerqueira, R., Lucchese, C., Magalhães, E., Del Sant, L. C., Tuena, M. A., Nakahira, C., Fava, V. A. R., Steglich, M., Abdo, G. L., Barbosa, M. G., Sarin, L. M., Lacerda, A. L. T.
Paywallmeta

A Systematic Review of Neurocognitive Effects of Subanesthetic Doses of Intravenous Ketamine in Major Depressive Disorder, Post-Traumatic Stress Disorder, and Healthy Population

This paper (2022) reviews the neurocognitive effects of subanesthetic doses of intravenous ketamine in pharmacological studies among healthy subjects and patients with PTSD or depression. No significant impairment in cognitive function was found in patients with depression and possible in those with PTSD. In contrast, immediate cognitive dysfunction was found in healthy subjects.

Published
Journal
Clinical Drug Investigation
Authors
Shiroma, P. R., Velit-Salazar, M. R., Vorobyov, Y.
Open Accessmeta

The Costs and Health Benefits of Expanded Access to MDMA-assisted Therapy for Chronic and Severe PTSD in the USA: A Modeling Study

This study (2022) uses a decision-analytic model to assess the cost and health benefits of expanded access to MDMA-assisted therapy (MDMA-AT) in the phase III clinical trials from MAPS. Expanding access to MDMA-AT to 25-75% of eligible patients was projected to avert 43,618-106,932 deaths and gain 3.3-8.2 million quality-adjusted life-years (QALYs).

Published
Journal
Clinical Drug Investigation
Authors
Avancena, A. L. V., Kahn, J. G., Marseille, E.

Quick Facts

Papers Indexed
3
h-Index
70
Open Access
No
Publisher
Adis International
Country
United Kingdom
Website
Visit